|
|
FDA Panel Does Not Recommend Dosing Change for Darbepoetin Alfa - Internal Medicine News Digital Network |
|
Internal Medicine News Digital NetworkAt the meeting, the FDA's Cardiovascular and Renal Drugs Advisory Committee was asked to review data from the TREAT study of mostly female patients in their ... |
|
|
Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors - PR Newswire (press release) |
|
PR Newswire (press release)Mr. Kenley is the recipient of over 30 patents and has been a frequent presenter at international symposia regarding the provision of dialysis, ... |
|
Research and Markets: Fresenius Medical Device Company Intelligence Report 2010 - Trading Markets (press release) |
|
Trading Markets (press release)... (FMC) concentrates on dialysis care, and the manufacture and marketing of products for the treatment of patients with end-stage renal disease (ESRD). ... |
|
US FDA advisory panel backs continued use of Amgen's Aranesp and Epogen pre ... - The Pharma Letter |
|
The Pharma Letter... remain on the market for anemia patients who do not yet require dialysis, despite an increased risk of stroke as identified in the TREAT clinical study. ...Amgen's Anemia Drug Aranesp Is Safe Before Kidney Dialysis, FDA Panel Says BloombergKidney Patients Not On Dialysis, FDA Advisers Recommend Continuation Of ... |
|
Advisory panel recommends FDA to allow the continued use of ESA labels - The Money Times |
|
The Money TimesThe current prescribing guidelines for darbepoetin use among chronic kidney disease patients not on dialysis was highly endorsed by the FDA's Cardiovascular ... |
|
|
|
|
<< Start < Prev 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 Next > End >>
|
|
Page 1263 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
